Momenta pharmaceuticals, inc. (MNTA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Collaboration revenue

8,889

8,182

6,391

5,182

4,113

42,822

14,884

13,031

4,852

64,608

24,090

23,570

26,614

34,195

29,144

26,430

19,850

22,393

13,795

44,900

8,562

21,179

9,336

10,950

10,785

12,750

10,751

4,361

7,603

12,728

5,102

21,863

24,228

29,455

87,945

87,496

78,172

51,961

2,795

Operating expenses:
Research and development

34,207

38,334

46,105

32,131

27,972

28,695

30,727

31,340

33,242

36,148

37,914

39,063

36,101

26,382

31,568

33,173

28,757

37,568

31,733

33,983

22,749

26,193

27,508

26,089

26,692

32,238

27,435

21,994

22,332

21,539

20,233

20,011

18,562

21,239

16,307

14,168

12,943

12,488

11,778

General and administrative

14,564

58,926

20,081

46,609

24,206

21,525

20,437

22,531

20,612

15,827

20,703

22,572

23,105

-46,301

15,758

14,896

15,647

14,373

12,459

13,329

7,890

11,125

11,103

11,219

11,717

10,848

8,977

11,516

9,716

9,375

10,999

12,353

10,955

9,715

11,480

9,205

8,310

7,325

5,959

Restructuring

0

-67

19

132

26

2,272

15,535

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other operating expense

786

-1,731

0

42,936

0

-

0

30,000

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (Loss) on Termination of Lease

-

-

13,720

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

49,557

95,462

52,485

121,808

52,204

52,492

66,699

83,871

53,854

51,975

58,617

61,635

59,206

44,547

47,326

48,069

44,404

51,941

44,192

47,312

30,639

37,318

38,611

37,308

38,409

43,086

36,412

33,510

32,048

30,914

31,232

32,364

29,517

30,954

27,787

23,373

21,253

19,813

17,737

Operating loss

-40,668

-87,280

-46,094

-116,626

-48,091

-9,670

-51,815

-70,840

-49,002

12,633

-34,527

-38,065

-32,592

-10,352

-18,182

-21,639

-24,554

-29,548

-30,397

-2,412

-22,077

-16,139

-29,275

-26,358

-27,624

-30,336

-25,661

-29,149

-24,445

-18,186

-26,130

-10,501

-5,289

-1,499

60,158

64,123

56,919

32,148

-14,942

Other income (expense):
Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

122

112

96

112

140

200

214

224

243

269

288

308

335

307

248

194

176

128

46

26

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

14

34

41

74

88

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68

88

62

62

62

62

60

55

58

60

-

-

-

-

-

-

-

-

-

-

Other income, net

1,113

580

1,551

2,657

3,248

1,425

1,515

955

1,371

1,126

1,339

1,157

833

51,891

638

653

542

384

347

190

200

158

174

202

262

274

279

301

329

508

308

335

307

246

180

142

87

-28

-62

Net loss

-39,555

-86,700

-44,543

-113,969

-44,843

-8,245

-50,300

-69,885

-47,631

13,759

-33,188

-36,908

-31,759

41,539

-17,544

-20,986

-24,012

-29,164

-30,050

-2,222

-21,877

-15,981

-29,101

-26,156

-27,362

-30,062

-25,382

-28,848

-24,116

-17,678

-25,822

-10,166

-4,982

-1,253

60,338

64,265

57,006

32,120

-15,004

Earnings Per Share [Abstract]
Basic and diluted net loss per share (in dollars per share)

-0.34

-0.85

-0.45

-1.16

-0.46

-0.07

-0.65

-0.91

-0.63

0.20

-0.44

-0.50

-0.46

0.61

-0.26

-0.31

-0.35

-0.44

-0.44

-0.04

-0.40

-0.31

-0.56

-0.51

-0.53

-0.58

-0.50

-0.57

-0.48

-0.35

-0.51

-0.20

-0.10

-

-

-

-

-

-

Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.03

1.21

1.29

1.15

0.72

-0.34

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.02

1.18

1.26

1.13

0.70

-0.34

Weighted average shares outstanding:
Weighted average shares used in computing basic and diluted net loss per share (in shares)

117,125

101,857

98,709

98,595

98,195

82,154

77,229

76,543

75,454

74,843

74,611

73,379

69,711

69,008

68,799

68,532

68,285

68,344

68,004

61,680

54,492

52,289

51,545

51,466

51,356

51,192

51,055

50,746

50,635

50,550

50,500

50,354

50,240

-

-

-

-

-

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50,134

50,034

49,708

49,532

44,719

44,069

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50,909

51,048

51,001

50,334

46,032

44,069

Comprehensive loss:
Comprehensive loss:
Net Income (Loss) Available to Common Stockholders, Basic

-39,555

-86,700

-44,543

-113,969

-44,843

-8,245

-50,300

-69,885

-47,631

13,759

-33,188

-36,908

-31,759

41,539

-17,544

-20,986

-24,012

-29,164

-30,050

-2,222

-21,877

-15,981

-29,101

-26,156

-27,362

-30,062

-25,382

-28,848

-24,116

-17,678

-25,822

-10,166

-4,982

-1,253

60,338

64,265

57,006

32,120

-

Net unrealized holding gain (loss) on available-for-sale debt securities

-415

-165

-58

264

342

77

137

274

-435

-187

52

-25

-66

-164

-36

149

133

-12

-4

18

18

-36

-26

37

-16

-95

98

-24

-65

-

185

-40

-

-

-

-

-

-

-

Comprehensive loss

-39,970

-86,865

-44,601

-113,705

-44,501

-8,168

-50,163

-69,611

-48,066

13,572

-33,136

-36,933

-31,825

41,375

-17,580

-20,837

-23,879

-29,176

-30,054

-2,204

-21,859

-16,017

-29,127

-26,119

-27,378

-30,157

-25,284

-28,872

-24,181

-17,738

-25,637

-10,206

-4,875

-1,186

60,130

64,394

56,953

-

-

Product revenue
Collaboration revenue

8,692

7,879

5,551

3,333

2,352

10,763

13,621

11,779

3,521

13,369

10,890

19,140

23,404

15,817

23,339

20,692

14,800

17,810

8,666

19,305

2,722

4,747

4,714

5,690

4,812

4,903

4,774

1,628

5,396

10,812

2,579

19,352

22,029

26,147

84,717

83,848

75,761

44,188

-

Research and development revenue
Collaboration revenue

197

303

840

1,849

1,761

32,059

1,263

1,252

1,331

51,239

13,200

4,430

3,210

18,378

5,805

5,738

5,050

4,583

5,129

25,595

5,840

16,432

4,622

5,260

5,973

7,847

5,977

2,733

2,207

1,916

2,523

2,511

2,199

3,308

3,228

3,648

2,411

7,773

2,795